Trials / Completed
CompletedNCT01485601
Safety and Efficacy Study of Botulinum Toxin Type A to Treat Glabellar Lines
A Randomised, Double-blind, Multi-centre, Phase II, Optimal Dose-finding Study to Determine the Safety and Efficacy of MT10109 (Clostridium Botulinum Toxin Type A) in Subjects With Moderate to Severe Glabellar Lines in Comparison to BOTOX®
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to find an optimal dose to determine the safety and tolerability of a single dose of MT10109(clostridium botulinum type A) administered by intramuscular injection in subjects with glabellar lines compared with the standard dose of BOTOX®
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MT10109 | Single dose intramuscular injection MT10109 vs Botox® |
Timeline
- Start date
- 2011-12-07
- Primary completion
- 2012-03-30
- Completion
- 2012-08-17
- First posted
- 2011-12-05
- Last updated
- 2024-02-22
- Results posted
- 2024-02-22
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01485601. Inclusion in this directory is not an endorsement.